Segment Forecast: Pharmaceutical Analytical Testing Services 2025–2030
The global healthcare analytical testing services market size was estimated at USD 15.7 billion in 2024 and is projected to reach USD 25.47 billion by 2030, growing at a CAGR of 8.41% from 2025 to 2030. This growth trajectory is underpinned by several key drivers, including the increasing outsourcing of analytical testing services by pharmaceutical and medical device companies, the rising number of clinical trials requiring advanced testing protocols, and a stronger industry focus on biosimilars as cost-effective alternatives to branded biologics.
The COVID-19 pandemic significantly accelerated industry expansion. During the crisis, the urgent need for vaccines, therapies, and diagnostic solutions led to a surge in demand for analytical testing services. In the post-pandemic period, the momentum has continued, with rapid advancements in drug development, preventive therapeutics, and vaccine innovation further boosting the need for specialized analytical testing.
Another important factor fueling market growth is the continuous wave of innovation and product development across the healthcare sector. The launch of new drugs, complex biologics, and combination products requires rigorous quality testing to meet regulatory standards. To address pricing pressures, shorter lead times to market, and heightened competitive intensity, many companies are increasingly outsourcing analytical testing to specialized service providers. This not only helps optimize operational costs but also ensures compliance with evolving global regulatory requirements.
The development of biosimilars, vaccine-combination products, and other novel therapeutics has particularly intensified the demand for comprehensive testing services, including bioanalytical, method validation, stability, and quality assurance testing. Furthermore, as pharmaceutical and medical device companies expand into new geographic regions, they must comply with local regulatory standards, which often necessitate additional testing to meet country-specific guidelines.
In terms of regional outlook, the U.S. market is projected to grow significantly, driven by the rising prevalence of chronic diseases such as cancer, diabetes, and cardiovascular disorders. This trend is increasing the demand for innovative therapeutics and, consequently, the analytical testing required to validate their safety, efficacy, and quality.
Key Market Trends & Insights:
• In 2024, North America emerged as the dominant region in the global healthcare analytical testing services market, securing the largest revenue share of 38.51%. This leadership position can be attributed to the region’s advanced healthcare infrastructure, strong presence of leading pharmaceutical and biotechnology companies, and substantial investments in drug development and clinical research. Favorable regulatory frameworks and the rapid adoption of innovative testing technologies have also strengthened North America’s standing in the global market.
• Within the region, the United States accounted for the highest share, underscoring its pivotal role in driving market growth. The U.S. benefits from a large patient population, increasing prevalence of chronic diseases, and a robust pipeline of new drug candidates. Additionally, the country hosts several contract research organizations (CROs) and specialized analytical testing providers, which cater to the growing demand from pharmaceutical and medical device manufacturers. The strong emphasis on regulatory compliance by the U.S. Food and Drug Administration (FDA) further contributes to the reliance on advanced analytical testing services.
• From a type perspective, the pharmaceutical analytical testing services segment dominated the market in 2024, capturing a revenue share of 58.44%. This dominance reflects the rising volume of drug discovery, biosimilar development, and generic drug production, all of which require extensive analytical testing for validation, safety, and quality assurance. The segment’s growth is also driven by the increasing trend of outsourcing testing activities to specialized providers, as pharmaceutical companies aim to reduce operational costs, shorten development timelines, and ensure compliance with stringent global regulations.
Order a free sample PDF of the Healthcare Analytical Testing Services Market Intelligence Study, published by Grand View Research.
Market Size & Forecast:
• 2024 Market Size: USD 15.7 Billion
• 2030 Projected Market Size: USD 25.47 Billion
• CAGR (2025-2030): 8.41%
• North America: Largest market in 2024
Key Companies & Market Share Insights:
Key players in the healthcare analytical testing services market are actively implementing a wide range of strategic initiatives to strengthen their market presence and secure a competitive advantage. These initiatives typically include acquisitions, geographic expansions, partnerships, agreements, and collaborative ventures with other industry stakeholders. By adopting such strategies, companies not only enhance their service portfolios but also expand their reach across different regions, ultimately contributing to overall market growth.
A notable example of this trend occurred in August 2024, when Eurofins CDMO Alphora Inc. announced the expansion of its drug product analytical services laboratory. This strategic move was aimed at increasing the company’s operational footprint and capacity to meet the growing demand for high-quality analytical testing services. The expansion demonstrates how leading players are continuously investing in infrastructure and advanced capabilities to better serve pharmaceutical and biotech clients, ensure regulatory compliance, and support the accelerated pace of drug development.
Such initiatives reflect a broader industry trend where major market participants are focusing on innovation, service diversification, and global expansion to align with the rising demand for comprehensive analytical testing solutions. These efforts are expected to play a critical role in driving sustained growth and shaping the competitive landscape of the healthcare analytical testing services market in the years ahead.
Key Players
• Thermo Fisher Scientific, Inc.
• ICON plc
• LabCorp
• Charles River Laboratories International, Inc.
• Syneos Health
• SGS SA
• Eurofins Scientific
• Pace Analytical Services, LLC
• Toxikon, Inc.
• Intertek Group
Explore Horizon Databook – The world's most expansive market intelligence platform developed by Grand View Research.
Conclusion:
The healthcare analytical testing services market is experiencing strong growth, driven by the increasing outsourcing of testing by pharmaceutical and medical device companies. Rising demand for biosimilars and the expansion of clinical trial activity are further fueling market expansion. The COVID-19 pandemic also accelerated this trend, prompting rapid advances in drugs and therapeutics and heightening the need for analytical testing. With growing regulatory scrutiny, innovation in product development, and a broader geographic expansion, the market is poised for continued robust growth and sustained momentum.
English
Arabic
Français
Português
Deutsch
Türkçe
Dutch
Italiano
Russian
Romaian